REG - Competition and Mkts - Merger Update: Cochlear Limited / Oticon Medical

Demant A/SAnnouncement

20/04/2023 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230420:nRST8380Wa&default-theme=true

RNS Number : 8380W  Competition and Markets Authority  20 April 2023

HEARING IMPLANTS DEAL COULD MEAN WORSE OUTCOMES FOR PATIENTS

CMA provisionally finds hearing implants merger could substantially reduce
competition, potentially leading to worse outcomes for patients and higher
costs for the NHS

The Competition and Markets Authority (CMA) has provisionally found a merger
between two of the biggest players in the UK's hearing implant sector could
lead to worse outcomes for the patients who rely on these life-changing
hearing implants and higher prices for the NHS.

The proposed merger of Cochlear Limited (Cochlear) and Oticon Medical, the
hearing implants division of Demant A/S (Demant), was referred for an in-depth
Phase 2 investigation, led by an independent inquiry group, in December 2022.
Following this, the CMA's provisional view is that the merger would likely
lead to a substantial reduction in competition for certain hearing loss
products - specifically bone conductive solution (BCS) products, which are
implants that bypass the damaged parts of the ear, converting sounds into
vibrations that are sent directly to the inner ear.

Competition between firms supplying BCS products is critical in driving
innovation and Cochlear and Oticon Medical are the only two suppliers of
'Passive' BCS products in the UK. The proposed merger would leave just a
single supplier of these products. Cochlear is by far the largest of only two
existing suppliers of a newer type of 'Active' BCS implant in the UK. Oticon
Medical has a rival Active BCS product in development. Together, the merged
businesses would dominate the supply of BCS products in the UK, with a share
well above 90 per cent.

This could lead to patients who need hearing implants losing out, with less
choice, reduced quality, or less innovation, as well as the NHS, the main
buyer of BCS products in the UK, in due course, potentially paying higher
prices. The CMA also looked at the impact on the supply of other hearing
implants (Cochlear Implants) at an earlier phase of investigation but found no
competition concerns in that sector.

Today's provisional findings followed the consideration of a wide range of
evidence, including concerns raised by clinics, who prescribe these products
to patients, and other market participants. During the next stage of its
investigation, the CMA will consider potential remedies for its concerns,
including whether halting Cochlear's purchase of Oticon Medical or preventing
the sale of the BCS part of that business is likely to be an effective way to
address the competition issues.

Chair of the CMA's independent inquiry group, Kip Meek said:

"We're concerned that this deal could seriously reduce competition with
patients having fewer suppliers to choose from, potentially losing out from
less innovation and lower product quality going forward, as well as in the
long term potentially costing the NHS and taxpayers more money.

"Any remedies offered by the parties that could effectively address our
competition concerns and any other adverse effects of the proposed deal will
be considered."

Any submissions to the CMA on practicable remedies to address the
provisionally identified substantial lessening of competition (SLC) need to be
received by 4 May. Views on our provisional findings are also welcome and must
be received by 11 May. All responses will be considered ahead of the CMA
issuing its final report, which is due by 5 June 2023.

For more information, visit the Cochlear/Oticon Medical merger inquiry page.
(https://www.gov.uk/cma-cases/cochlear-slash-oticon-merger-inquiry)

Notes to Editors:

1.         All media enquiries should be directed to the CMA press
office by email on press@cma.gov.uk (mailto:press@cma.gov.uk) , or by phone
on 020 3738 6460.

2.         Cochlear (Cochlear Limited) manufactures and supplies
hearing devices used by healthcare professionals to treat a range of types of
hearing loss, with a particular focus on cochlear implants (CI) and BCS
(together, hearing implants).

3.         Demant (Demant A/S) develops, manufactures, and supplies
hearing implants (both CI and BCS) through Oticon Medical. Demant also
supplies hearing aids, operates clinics providing hearing care solutions, and
supplies hearing diagnostic products and audio solutions for enterprise,
gaming, and air traffic control.

4.        BCS products are used in the treatment of conductive, mixed,
and single-sided hearing loss. They bypass damaged parts of the ear by using a
sound processor that converts sounds into vibrations that are sent directly to
the inner ear. There are two types of BCS products: Passive and Active. They
differ in the way they connect the transducer (that translates sounds into
vibrations transmitted through the bone) to the sound processor.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MERGPURCCUPWPWB